Discover
SEPN
Septerna, Inc.
34.61
2 x 25.10
2 x 42.81
bid
ask
+
1.12
3.34%
2 @ 04:00 PM
34.61 +0.00 (0.00%)
| Ytd | 24.14% | |
| 1y | 226.51% |
33.02
day range
35.17
10.48
52 week range
37.99
| Open | 33.45 | Prev Close | 33.49 | Low | 33.02 | High | 35.17 | Mkt Cap | 1.56B |
| Vol | 429.40K | Avg Vol | 378.97K | EPS | -0.80 | P/E | N/A | Forward P/E | -12.59 |
| Beta | N/A | Short Ratio | 8.13 | Inst. Own | 102.65% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 29.41 | 200-d Avg | 25.60 | 1yr Est | 44.89 |
SEPN News
benzinga.com
Guggenheim Maintains Buy on Septerna, Lowers Price Target to $45
Guggenheim analyst Seamus Fernandez maintains Septerna (NASDAQ:SEPN) with a Buy and lowers the pr
benzinga.com
HC Wainwright & Co. Reiterates Buy on Septerna, Maintains $40 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Septerna (NASDAQ:SEPN) with a Buy a
benzinga.com
Truist Securities Maintains Buy on Septerna, Raises Price Target to $43
Truist Securities analyst Srikripa Devarakonda maintains Septerna (NASDAQ:SEPN) with a Buy and ra
fool.com
Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?
15,000 shares were exercised and sold for a total of ~$533,000 on June 22, 2026, at a weighted avera
benzinga.com
Raymond James Maintains Strong Buy on Septerna, Raises Price Target to $53
Raymond James analyst Martin Auster maintains Septerna (NASDAQ:SEPN) with a Strong Buy and raises
benzinga.com
Septerna Announces First Detailed Preclinical Characterization Of SEP-479 Accepted For Oral Presenta
Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G prote